|Bid||5.280 x 500|
|Ask||5.290 x 800|
|Day's Range||5.260 - 5.640|
|52 Week Range||2.600 - 9.250|
|PE Ratio (TTM)||-8.45|
|Earnings Date||Aug 2, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||8.38|
Successful late-stage data on Shire Plc's , long-acting preventative treatment for hereditary angioedema (HAE) brings the Dublin-based drugmaker one step closer to U.S. approval, it said on Thursday. The drug, lanadelumab, which is expected to generate more than $2 billion in peak sales will help Shire protect and grow its existing HAE franchise, which accounts for about 10 percent of its profit, analysts said. In Shire's late-stage study, three dosing arms of lanadelumab (150 or 300 mg every four weeks or 300 mg every two weeks) were tested against a placebo in 125 patients.
Investors in BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately.
Q1 2017 BioCryst Pharmaceuticals Inc Earnings Call